Sinja Taavitsainen

2.0k total citations · 1 hit paper
17 papers, 899 citations indexed

About

Sinja Taavitsainen is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Sinja Taavitsainen has authored 17 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Sinja Taavitsainen's work include Prostate Cancer Treatment and Research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). Sinja Taavitsainen is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Prostate Cancer Diagnosis and Treatment (4 papers). Sinja Taavitsainen collaborates with scholars based in Finland, Canada and Australia. Sinja Taavitsainen's co-authors include Matti Nykter, Alexander W. Wyatt, Matti Annala, Kim N., Bernhard J. Eigl, Muhammad Zulfiqar, Joanna Vergidis, Daygen L. Finch, Martin Gleave and Conrad D. Oja and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sinja Taavitsainen

16 papers receiving 893 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Peers

Sinja Taavitsainen

PRM

ONCOL

RNMI

Samanta Salvi Italy

Evan W. Warner Canada

Ines Figueiredo United Kingdom

Mary Anne Fenton United States

Prateek Mendiratta United States

Chenfei Chi China

Curtis Dunshee United States

Francesco Lasorsa Italy

Jawad Manekia United States

V. Papadimitrakopoulou United States

Samanta Salvi Italy

Sinja Taavitsainen

491 ×0.7

PRM

551 ×1.2

442 ×1.8

300 ×1.2

ONCOL

83 ×0.6

RNMI

Citations per year, relative to Sinja Taavitsainen Sinja Taavitsainen (= 1×) peers Samanta Salvi

Countries citing papers authored by Sinja Taavitsainen

Since Specialization

Citations

This map shows the geographic impact of Sinja Taavitsainen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sinja Taavitsainen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sinja Taavitsainen more than expected).

Fields of papers citing papers by Sinja Taavitsainen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sinja Taavitsainen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sinja Taavitsainen. The network helps show where Sinja Taavitsainen may publish in the future.

Co-authorship network of co-authors of Sinja Taavitsainen

This figure shows the co-authorship network connecting the top 25 collaborators of Sinja Taavitsainen. A scholar is included among the top collaborators of Sinja Taavitsainen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sinja Taavitsainen. Sinja Taavitsainen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kaljunen, Heidi, Sinja Taavitsainen, Ville Paakinaho, et al.. (2023). Fanconi anemia pathway regulation by FANCI in prostate cancer. Frontiers in Oncology. 13. 1260826–1260826. 3 indexed citations

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

Ketola, Kirsi, Heidi Kaljunen, Sinja Taavitsainen, et al.. (2021). Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Research. 81(19). 4901–4909. 8 indexed citations

Taavitsainen, Sinja, et al.. (2021). Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers. 13(13). 3325–3325. 26 indexed citations

Vandekerkhove, Gillian, Jean‐Michel Lavoie, Matti Annala, et al.. (2021). Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications. 12(1). 184–184. 109 indexed citations

Woodcock, Dan J., Sinja Taavitsainen, Matti Kankainen, et al.. (2020). Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nature Communications. 11(1). 5070–5070. 42 indexed citations

Warner, Evan W., Steven Yip, Matti Annala, et al.. (2020). Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations. Clinical Cancer Research. 26(11_Supplement). PR09–PR09. 1 indexed citations

Aragón, Isabel M., Daniel Khalaf, Rebeca Lozano, et al.. (2020). HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.. Journal of Clinical Oncology. 38(15_suppl). 5525–5525. 1 indexed citations

Khalaf, Daniel, Matti Annala, Sinja Taavitsainen, et al.. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology. 20(12). 1730–1739. 213 indexed citations

10.

Lavoie, Jean‐Michel, Gillian Vandekerkhove, Matti Annala, et al.. (2019). Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC). Annals of Oncology. 30. v376–v376.

11.

N., Kim, Sinja Taavitsainen, Nayyer Iqbal, et al.. (2019). Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.. Journal of Clinical Oncology. 37(15_suppl). 5003–5003. 3 indexed citations

12.

Fu, Songbin, Andrew J. Murtha, Cameron Herberts, et al.. (2019). Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC). Annals of Oncology. 30. v347–v347. 1 indexed citations

13.

Taavitsainen, Sinja, Matti Annala, Elisa M. Ledet, et al.. (2019). Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology. 3(3). 1–9. 36 indexed citations

14.

Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457. 347 indexed citations breakdown →

15.

Annala, Matti, Sinja Taavitsainen, Gillian Vandekerkhove, et al.. (2018). Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology. 1(1). 122–122. 18 indexed citations

16.

Taavitsainen, Sinja, et al.. (2018). Interleukin 10 mutant zebrafish have an enhanced interferon gamma response and improved survival against a Mycobacterium marinum infection. Scientific Reports. 8(1). 10360–10360. 34 indexed citations

17.

Chi, K.N., Sinja Taavitsainen, Nayyer Iqbal, et al.. (2018). A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii271–viii272. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact